Second Cellular Processing Patent.
RANCHO CORDOVA, Calif., November 28, 2017 -- The U.S. Patent and Trademark Office issued a patent to Cesca Therapeutics for a method ogf separating rare, therapeutically critical target cells from blood, bone marrow, leukapheresis product, and other cell sources, while maintaining the viability of the cells under asceptic conditions.
Cesca (KOOL), which specializes in automated cell processing, said patent No. 9,821,111 is titled "Cell Separation Devices, Systems, and Methods."
This advanced cell separation technology, known as Buoyancy-Activated Cell Separation, or BACS, is key to the ongoing development of Cesca's CAR-TXpress platform.
The company said the patent allows it to address the unique needs of potential partners, including CAR-T manufacturers, medical device companies, distributors and academic institutions.
The patent is Cesca's second in a series relating to its X-BACS technology. On July 28, 2017, Cesca announced that SynGen, Inc., which the company acquired on July 10, 2017, had been awarded U.S. patent No. 9,695,394 covering the X -BACS apparatus. That patent also allows for the automated isolation of cells with low density surface antigens, which was previously a major cellular manufacturing challenge.
Cesca's X-BACS technology employs microscopic bubbles to isolate a specific cell type from a complex mixture of cells, such as blood.
These microbubbles bear antibodies on their surface, enabling them to bind specifically to a single desired target cell type. When coated with microbubbles, the target cells float to the top of the host liquid, while non-target cells sink to the bottom - a process that can be accelerated by centrifugation.
Subsequent collection of the floating target cell layer and release of the cells from their microbubbles provides a highly-purified preparation of just the cells of interest, with high recovery efficiency while retaining cell viability.
Stock Offering Announced
In related news, Cesca announced a proposed registered public offering of its common stock, subject to market and other conditions.
Net proceeds from the sale will be used for general corporate purposes, including working capital.
The company priced the offering of up to an aggregate of 900,000 shares of the common stock at a price to the public of $3.00 per share. The offering was expected to close on or about December 1, 2017, subject to the satisfaction of customary closing conditions.
|Printer friendly Cite/link Email Feedback|
|Publication:||Stem Cell Business News|
|Date:||Dec 11, 2017|
|Previous Article:||Potential U.S. Patent On Multi-Organoid Bioreactor Platform.|
|Next Article:||Semma Therapeutics Raises $114M In Series B Financing.|